Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

BMC Gastroenterology

Research Article

Ana S Sandoval-Rodríguez¹  Lucia Flores-Contreras¹  M Guadalupe Sanchez-Parada¹  Mayra G Mena-Enriquez¹  Arnulfo Álvarez-Álvarez¹  Silvia Lucano-Landeros¹  Juan Armendáriz-Borunda²  Inmaculada Arellano-Olivera³ 

[1] Departamento de Biología Molecular y Genómica, Instituto de Biología Molecular en Medicina y Terapia Génica, CUCS, Universidad de Guadalajara, Sierra Mojada # 950, 44281, Guadalajara, Jalisco, Mexico;Departamento de Biología Molecular y Genómica, Instituto de Biología Molecular en Medicina y Terapia Génica, CUCS, Universidad de Guadalajara, Sierra Mojada # 950, 44281, Guadalajara, Jalisco, Mexico;INNOVARE, Guadalajara, Jalisco, Mexico;Departamento de Biología Molecular y Genómica, Instituto de Biología Molecular en Medicina y Terapia Génica, CUCS, Universidad de Guadalajara, Sierra Mojada # 950, 44281, Guadalajara, Jalisco, Mexico;Unidad Médica de Alta Especialidad, Hospital de Especialidades Centro Medico Nacional de Occidente, Guadalajara, Jalisco, Mexico;

关键词: Pirfenidone;    Liver fibrosis;    Necroinflammation;    Cytokines;    Cannabinoid receptor 1;    Cannabinoid receptor 2;    Chronic hepatitis C;   

DOI  :  10.1186/1471-230X-14-131

 received in 2013-08-17, accepted in 2014-07-14,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe aim of this study was to assess whether two-years treatment with Pirfenidone influences necroinflammation, fibrosis and steatosis, serum levels of TGF-β1, IL-6, TNF-α and CB1 and CB2 gene expression, in patients with chronic hepatitis C (CHC).MethodsTwenty-eight patients out of 34 with CHC virus infection were enrolled in the study and received Pirfenidone (1200 mg/day) for 24 months. Six patients dropped out after 12 months of PFD. Liver biopsies and serum samples were obtained at the beginning and end of treatment. Modified HAI was calculated. CB1 and CB2 gene expression was correlated with fibrosis progression alongside with necroinflammation and steatosis. TGF-β1, IL-6, TNF-α and liver transaminases were measured in serum at two-months intervals. HCV genotype and viral load were also assessed. Quality of life was evaluated by SF36 questionnaires and the prognosis of disease was assessed with Child-Pugh score. The Wilcoxon test matched-pair signed ranks were used to analyze the outcomes.ResultsIntention to treat analyses were performed for biochemistry and clinical parameters. At the end of treatment, necroinflammation grading was reduced in an average of 3.2 points in 82% of patients (p < 0.05) and Ishak’s fibrosis stage decreased 2-points average in 67% of patients (p < 0.05). Steatosis decreased in 61% of patients. IL-6 and TGF-β1 serum levels decreased significantly in 93% and 67% of patients (p < 0.05), respectively, while TNF-α diminished in 47% of patients. ALT and AST tended to normalize in 81% of patients; CB2 mRNA levels increased in 86% and CB1 expression diminished in 29% of patients. Both, quality of life and Child-Pugh score improvements were reported in all patients.ConclusionsPirfenidone for two years benefits CHC patients and improves inflammation, fibrosis and steatosis in higher number of patients as previously shown for 12-months treatment with PFD. Additionally, PFD improved TGFβ1 and IL-6 levels and diminished liver expression of anti-fibrogenic receptor CB2.Trial registrationClinicalTrials.gov identifier: NCT02161952. Protocol Registration Date: 06/11/2014.

【 授权许可】

Unknown   
© Flores-Contreras et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.